



HAL
open science

3D Chemical Shift-Encoded MRI for Volume and Composition Quantification of Abdominal Adipose Tissue During an Overfeeding Protocol in Healthy Volunteers

Angeline Nemeth, Berenice Segrestin, Benjamin Leporq, Kévin Seyssel, Khuram Faraz, Valerie Sauvinet, Emmanuel Disse, Pierre-Jean Valette, Martine Laville, Hélène Ratiney, et al.

► **To cite this version:**

Angeline Nemeth, Berenice Segrestin, Benjamin Leporq, Kévin Seyssel, Khuram Faraz, et al.. 3D Chemical Shift-Encoded MRI for Volume and Composition Quantification of Abdominal Adipose Tissue During an Overfeeding Protocol in Healthy Volunteers. *Journal of Magnetic Resonance Imaging*, 2019, 49 (6), pp.1587-1599. 10.1002/jmri.26532 . hal-01917470

HAL Id: hal-01917470

<https://hal.science/hal-01917470>

Submitted on 13 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title: 3D chemical shift-encoded MRI for volume and composition**
2 **quantification of abdominal adipose tissue during an overfeeding**
3 **protocol in healthy volunteers**

4 **Author Names and Degrees:**

5 Angeline Nemeth¹, MS, Bérénice Segrestin^{2,3}, MD, Benjamin Leporq¹, PhD, Kevin Seyssel⁴,
6 PhD, Khuram Faraz¹, PhD, Valérie Sauvinet², MS, Emmanuel Disse^{2,3}, MD-PhD, Pierre-Jean
7 Valette⁵, MD-PhD, Martine Laville^{2,3}, MD-PhD, Hélène Ratiney¹, PhD, and Olivier Beuf¹,
8 PhD

9 **Author Affiliations:**

10 ¹Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS,
11 Inserm, CREATIS UMR 5220, U1206, F69621, Lyon, France, ²Centre de Recherche en
12 Nutrition Humaine Rhône-Alpes (CRNH-RA), Centre Hospitalier Lyon Sud, Pierre-Bénite,
13 Lyon, France, ³Institut National de la Santé et de la Recherche Médicale Unit 1060, CarMeN
14 Laboratory, Lyon 1 University, Oullins, France, ⁴Department of Physiology, Faculty of
15 Biology and Medicine, University of Lausanne, Lausanne, Switzerland, ⁵Hospices Civils de
16 Lyon, Département d'imagerie digestive, CHU Edouard Herriot, Lyon, France

17 **Correspondence to:**

18 Olivier Beuf, Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint
19 Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, F69621, Lyon, France

20 Email: Olivier.beuf@creatis.insa-lyon.fr

21 **Grant Support:**

22 LABEX PRIMES (ANR-11-LABX-0063), the "Investissements d'Avenir" program ANR-11-
23 IDEX-0007, IHU OpéRa (ANR-10-IBHU-0004).

24 **Running Title:** Quantification of adipose tissue by CSE-MRI

25

26 **Abstract**

27 BACKGROUND

28 Overweight and obesity are a major worldwide health concern characterized by an abnormal
29 accumulation of fat in adipose tissue (AT) and liver.

30 PURPOSE

31 To evaluate the volume and the fatty acid (FA) composition of the subcutaneous adipose
32 tissue (SAT) and the visceral adipose tissue (VAT) and the fat content in the liver from 3D
33 CSE-MRI acquisition, before and after a 31 days overfeeding protocol.

34 STUDY TYPE

35 Prospective and longitudinal study.

36 SUBJECTS

37 21 non-obese healthy male volunteers

38 FIELD STRENGTH/SEQUENCE

39 A 3D spoiled-gradient multiple echo sequence and STEAM sequence were performed at 3T.

40 ASSESSMENT

41 AT volume was automatically segmented on CSE-MRI between L2 to L4 lumbar vertebrae
42 and compared to the DEXA measurement. CSE-MRI and MRS data were analyzed to assess
43 the proton density fat fraction (PDFF) in the liver and the FA composition in SAT and VAT.
44 Gas chromatography-mass spectrometry (GC-MS) analyses were performed on 13 SAT
45 samples as a FA composition countermeasure.

46 STATISTICAL TESTS

47 Paired t-test, Pearson's correlation coefficient and Bland Altman plot were used to compare
48 measurements.

49 RESULTS

50 SAT and VAT volumes significantly increased ($p < 0.001$). CSE-MRI and DEXA
51 measurements were strongly correlated ($r = 0.98$, $p < 0.001$). PDFFF significantly increased in the
52 liver (+1.35, $p = 0.002$ for CSE-MRI, +1.74, $p = 0.002$ for MRS). FA composition of SAT and
53 VAT appeared to be consistent between localized-MRS and CSE-MRI (on whole segmented
54 volume) measurements. Significant difference between SAT and VAT FA composition was
55 found ($p < 0.001$ for CSE-MRI, $p = 0.001$ for MRS). MRS and CSE-MRI measurements of the
56 FA composition were correlated with the GC-MS results (for ndb: $r_{\text{MRS/GC-MS}} = 0.83$, $p < 0.001$, $r_{\text{CSE-}}$
57 $\text{MRI/GC-MS}} = 0.84$, $p = 0.001$; for nmdb: $r_{\text{MRS/GC-MS}} = 0.74$, $p = 0.006$, $r_{\text{CSE-MRI/GC-MS}} = 0.66$, $p = 0.020$)

58 DATA CONCLUSION

59 The follow-up of liver PDFFF, volume and FA composition of AT during an overfeeding diet
60 was demonstrated through different methods. The CSE-MRI sequence associated with a
61 dedicated post-processing was found reliable for such quantification.

62 **Key words (3 to 6):** Fatty acid composition, in vivo, MR spectroscopy, chemical shift-
63 encoded imaging, overfeeding, gas chromatography-mass spectrometry

64

65 Terminology

- 66 • AT, adipose tissue
- 67 • FA, fatty acid;
- 68 • SFA, saturated fatty acid;
- 69 • MUFA, monounsaturated fatty acid;
- 70 • PUFA, polyunsaturated fatty acid;
- 71 • *ndb*, number of double bonds;
- 72 • *nmidb*, number of methylene-interrupted double bonds;
- 73 • SFA_{indx}, proportion of saturated fatty acid estimated by *ndb* and *nmidb*;
- 74 • MUFA_{indx}, proportion of monounsaturated fatty acid estimated by *ndb* and *nmidb*;
- 75 • PUFA_{indx}, proportion of polyunsaturated fatty acid estimated by *ndb* and *nmidb*;
- 76 • CL, chain length;
- 77 • SAT, subcutaneous abdominal adipose tissue;
- 78 • VAT, visceral adipose tissue;
- 79 • PDFF, proton density fat fraction
- 80 • CSE-MRI, chemical shift-encoded magnetic resonance imaging
- 81 • CV, coefficient of variation
- 82 • GC-MS, gas chromatography-mass spectrometry
- 83 • IFCC, International Federation of Clinical Chemistry
- 84 • TAG, triacylglycerol
- 85 • SNR, signal to noise ratio

86

87

88 Text (5199words):**89 INTRODUCTION**

90 Obesity is a complex disease combining genetic factors still poorly identified and
91 environmental factors mainly related to diet and physical inactivity(1). Overweight and
92 obesity are major worldwide health issues increasing the risk to develop pathologies such as
93 diabetes, cardiovascular disease and Non Alcoholic Fatty Liver Diseases (NAFLD). Although
94 obesity is defined by a body mass index (BMI) greater than or equal to 30 kg/m^2 for humans,
95 distribution of adipose tissue is decisive in the assessment of cardio-metabolic risk factors(2).
96 People with abdominal fat accumulation have commonly an altered metabolic profile (also
97 called metabolic syndrome). The expansion of visceral adipose tissue (VAT), leading to an
98 increase in waist circumference, is associated with a higher risk to develop insulin resistance
99 and type 2 diabetes unlike the expansion of subcutaneous adipose tissue (SAT) (3). BMI is
100 not relevant to predict these risks because no distinction is made between fat mass and lean
101 mass. Dual-energy X-ray absorptiometry (DEXA) allows measurement and distribution of
102 body fat. To be more accurate, some imaging modalities like Magnetic Resonance Imaging
103 (MRI) and computed tomography (CT) (4) can assess independently the distribution of SAT
104 and VAT unlike DEXA. The major drawback of CT is the ionizing radiation exposure of
105 patients whereas MRI allows the measurement of fat volumes without any known short- or
106 long-term side effects. Over the last decades, various segmentation methods of SAT and VAT
107 volume have emerged based on various MRI acquisition such as T1-weighted, T2-weighted or
108 chemical-shift encoded imaging (CSE-MRI), each one with advantages and disadvantages (5).
109 T1-weighted and T2-weighted image contrast varies with B0 field strength which can be a
110 problem in the reproducibility of the results in multi-center studies. CSE-MRI can give an
111 accurate estimate of proton density fat fraction (PDFF) which is a biomarker (6). Beyond
112 volume quantification, the lipid composition of these tissues could be a relevant biomarker

113 (7).When analyzed by mass spectrometry (8), fatty acid composition (FA) of AT has been
114 associated with AT function (adipogenesis, differentiation, lipid metabolism) with large
115 differences between SAT and VAT, shedding light on the pathophysiology of metabolic
116 diseases(8, 9).This analysis requires access to human tissue, and cannot be widely proposed.
117 Surrogate markers of lipid composition of AT are needed. Magnetic Resonance Spectroscopy
118 (MRS) is able to provide non-invasively the proportions of saturated (SFA), monounsaturated
119 (MUFA) or polyunsaturated (PUFA) fatty acids. Recent studies (10–12) demonstrated the
120 feasibility of assessing the composition of fat based on multiple gradient echo imaging also
121 named chemical shift-encoded MRI (CSE-MRI). Studies focusing on liver diseases have
122 extensively compared the MRS and MRI methods for the quantification of the PDFFF (13–15).

123 The aim of this work was to assess CSE-MRI method to detect content and composition
124 changes of fat storage in healthy volunteers during a 31 days overfeeding protocol while
125 comparing CSE-MRI results with DEXA, MRS and GC-MS measurements.

126 **MATERIALS AND METHODS**

127 *Overfeeding Protocol*

128 From February 2014 to December 2016, volunteers were recruited via notice boards and
129 electronic bulletins. To be eligible, participants had to be a man aged between 18 and 55 years
130 with a BMI between 23.0 kg/m² and 27.0 kg/m² and low physical activity. Volunteers were
131 excluded if they had personal medical history of type 1 or 2 diabetes. Written informed
132 consent was obtained from all the subjects. All men underwent 31 days of high-sucrose and
133 high-fat overfeeding by eating the equivalent of +50% of their daily energy requirements
134 while maintaining their eating and sport activity habits. This protocol was validated by an
135 ethics committee and was registered on the clinicaltrials.gov site (NCTXXXXXXXXX). Only
136 results from subjects with a placebo complement to their eating are reported in this paper.

137 *Imaging And Spectroscopy Protocol*

138 *MRI*

139 Subjects underwent two 3D spoiled-gradient multiple echo sequence on a 3T Ingenia Philips
140 system (Philips Healthcare, Best, the Netherlands): one before the overfeeding at day 0
141 (MRI1) and the second at day 31 (MRI2). 3D MRI acquisitions parameters were the
142 following: 8 echoes ($n \times 1.15$ ms TE with $n=1, \dots, 8$), 5° flip angle, 10.3 ms
143 TR, $384 \times 420 \times 320$ mm³ FOV, $256 \times 256 \times 80$ matrix size, 20.8 s scan time. This
144 acquisition was made in breath-holding. The subjects were in supine position with both arms
145 aligned along the body. For signal reception, a 32-channel abdominal body-array coil was
146 used. The acquisition was performed on the abdominal region, encompassing L1 to L5 lumbar
147 vertebrae and the liver.

148 *DEXA*

149 Fat weight and lean weight were determined by dual-energy X-ray absorptiometry (DEXA,
150 Lunar Prodigy GE Medical Systems). Subjects underwent two whole-body DEXA scanning:
151 one before the overfeeding (day-7 or day 0) and the other after the overfeeding (day 28 or day
152 31). Fat weight of android region from DEXA was compared to CSE-MRI measurement. The
153 android region was the area between the ribs and the pelvis (top of the iliac crest)(16) and was
154 close to the defined region in MRI method.

155 *Spectroscopy*

156 Subjects underwent two STEAM sequences in a row for test-retest using respiratory
157 triggering with voxel placed in liver, VAT and SAT tissues (parameters in the caption of
158 Figure 1). This protocol was performed at the baseline examination (MRS1) and repeated
159 after the overfeeding (MRS2).

160 *FA Analysis By Gas Chromatography-Mass Spectrometry (GC-MS)*

161 The total FA compositions of the SAT samples were determined independently by GC-MS.
162 FAs profiles were obtained from the triacylglycerol (TAG) fraction which is representative of
163 the intracellular content of the SAT.

164 *Sample Collect*

165 A needle biopsy of abdominal SAT was performed 10cm from the umbilicus, under local
166 anesthesia (1% lidocaine, BD microlance 21G 1^{1/2} inch, 0.8*40mm needles), for 300mg to 1g
167 adipose tissue samples. Subsequent biopsy was taken contralaterally. Fat samples were
168 immediately frozen in liquid nitrogen and stored at -70 °C.

169 *Sample Preparation*

170 Approx. 50 mg cryogenically crushed sample were weighed exactly before proceeding to the
171 total lipid extraction using 6 mL of a mixture of chloroform/methanol (2:1, vol:vol) according
172 to the Folch method (17). An internal standard (TAG C17:0, glycerol triheptadecanoate),
173 corresponding to 60µg of C17:0 /mg of tissue, was added in order to quantify the FAs
174 occurring from the TAG fraction. The TAG fraction was then obtained from 1/40^e of the total
175 lipid extract by thin-layer chromatography on silica-gel plates with a mobile phase of hexane:
176 diethyl ether:acetic acid (80:20:1, vol:vol:vol) and was submitted to direct methylation
177 according to a modification of the technique described elsewhere (18).

178 *GC-MS Analysis*

179 The amounts of FAs were measured by GC/EI-MS (EI: electron ionization) using a
180 quadrupole mass spectrometer (model MS 5975, Agilent Technologies, Massy, France)
181 connected to a gas chromatograph (model GC6890, Agilent Technologies) equipped with a
182 fused-silica column (SP2380, 60 m x 0.20 mm x 0.25 µm film thickness; Supelco). Injection
183 (1 µL) was performed in splitless mode at 240 °C. FAs were separated with the following

184 oven program: (a) 50 °C for 1 min; (b) increase at a rate of 20 °C.min⁻¹ to 175 °C and hold for
 185 9.75 min; (c) increase at a rate of 2 °C.min⁻¹ to 217 °C and hold at 217 °C for 1 min. Mass
 186 spectra were obtained from the Total Ion Chromatogram (TIC) over a mass range of m/z 35–
 187 450.

188 *Comparison With NMR Methods*

189 In order to obtain comparable results between the GC-MS and NMR methodologies, the mean
 190 number of double bound (ndb_{GC}) and the mean of methylene-interrupted double bound
 191 ($nmidb_{GC}$) by triglyceride chain were computed as:

$$ndb_{GC} = \left(\sum_i^N ndb_i * p_i \right) * 3$$

$$nmidb_{GC} = \left(\sum_i^N nmidb_i * p_i \right) * 3$$

$$CL_{GC} = \left(\sum_i^N CL_i * p_i \right)$$

192 Where N was the number of the different type of FAs analyzed, ndb_i number of double bound
 193 of the i^{th} FA, $nmidb_i$ number of methylene-interrupted double bound of the i^{th} FA, CL_i the
 194 number of carbon in FA chain and p_i the relative proportion of the i^{th} FA.

195 *MRS Signal Processing And Analysis*

196 For spectrum acquired in SAT, similarly to the eddy current correction performed usually
 197 using the water phase signal, the time dependent phase variation of the signal of the first echo
 198 (TE=14ms) was corrected with the time dependent phase of the second echo (TE=24ms)
 199 which was less impacted by eddy current effects. This correction was possible because 1) the
 200 methylene -CH_{2n}- amplitude peak was the unique preponderant component, and 2) $\Delta TE = TE_2 -$

201 TE_1 was small compared to the lipid T2 and $1/J$ ($4 < J < 8\text{Hz}$, for in vivo FA spectral). This
202 correction needs exactly the same frequency content in the two spectra. So it was not applied
203 to the spectra from the VAT tissue because of the presence of a low water peak in some case.
204 In this latter case, the signal is probably altered due to peristalsis of the digestive tract from
205 one echo to the other which could explain why the water peak contribution varies from one
206 echo to the other. The quantification method, described shortly below and in (19), was
207 applied only on the spectrum of the first echo; the other echoes were acquired to estimate the
208 T_{2k} s, i.e the apparent T2 of each resonating lipid component ($k \in [1, \dots, 10]$). T_{2k} estimations
209 were made in the frequency domain, for each resonance, with a nonlinear least-square
210 estimation of the mono-exponential $S_k(TE) = S_{0k} \cdot \exp(-TE/T_{2k})$, where $S_k(TE)$ was the
211 measured integral of the k^{th} peak at TE (6 echoes varying regularly from 14ms to 64ms by
212 step of 10ms), S_{0k} the amplitude at $TE=0$ and T_{2k} the T2 of the k^{th} peak.

213 To quantify the PDFF in the liver, a Voigt (20) model with 2 peaks was applied on the
214 spectrum to estimate the amplitude of the water peak at 4.7ppm and the main peak of fat at
215 1.3 ppm. The PDFF was then computed by $\text{PDFF} = A_f / (A_w + A_f)$. The non-linear least square
216 optimization of the Voigt model was applied on the 200 first points of the FID (~100ms and
217 omitting the first point).

218 The MRS results reported in the rest of the paper are the mean quantification values of the
219 two consecutive acquisitions.

220 ***CSE-MRI Processing And Analysis***

221 *Automated Segmentation Method Of SAT And VAT*

222 Automatic segmentation was simultaneously performed exploiting the PDFF mapping
223 described in (21) as well as the first and second echo images (out of phase and in phase
224 respectively) to separate SAT from VAT. An operator determined the slices corresponding to

225 the upper of L2 and the lower of L4. A first reference slice chosen by the user in the stack of
226 images was segmented automatically. Manual correction can be done if necessary. Thanks to
227 3D acquisition and low partial volume effect, the mask of a slice (reference slice for the
228 beginning) was used as *a priori* knowledge for the determination of the next slice mask using
229 the *Lankton* level set algorithm (22). After segmentation, two binary masks were created one
230 for SAT and the other for VAT and multiplied to the PDFF map (PDFF_{SAT} and PDFF_{VAT}
231 map). Only pixels with a PDFF higher than 55% were kept in order to remove vertebrae and
232 intramuscular adipose tissue contributions to VAT volume. In some regions of large static
233 field inhomogeneity, at the level of iliac crests, fat/water swaps led to erroneous PDFF
234 contribution in particular in SAT. In this case, a manual correction was made.

235 *SAT, VAT And TAT Volumes*

236 The SAT and VAT masks were binary images. The total abdominal adipose tissue (TAT) was
237 calculated by adding the SAT and VAT masks. Adipose tissue volumes were calculated by
238 counting all pixels in the mask of SAT (or VAT or TAT) considering that each pixel
239 represented 100% of fat and multiplying by the elementary volume (voxel of $9.84 \cdot 10^{-3} \text{ cm}^3$).
240 The total abdominal adipose tissue (TAT) volume delimited by the L2 and L4 vertebrae was
241 converted into mass using the assumed an average density of 0.92 g/cm^3 (23) and compared to
242 the DEXA measurement on android region. The total fat content in android region
243 considering the PDFF of the tissues (adipose tissues, muscles and vertebrae) was also
244 analyzed and computed as the sum of each element of the matrix defined by
245 $(\text{PDFF}_{\text{SAT}} + \text{PDFF}_{\text{VAT}}) * 9.84 \cdot 10^{-3} \text{ cm}^3 * 0.92 \text{ g/cm}^3$.

246 *Fat Content In The Liver*

247 The region of interest (ROI) in the liver was manually defined on a unique slice on which the
248 right hepatic portal vein appeared the largest in axial plane. The mean value of PDFF in this
249 ROI was computed. To compare CSE-MRI and MRS measurements, the mean PDFF value

250 was computed in an ROI corresponding to the MRS voxel size and labeled “localized CSE-
 251 MRI measurement”. This ROI was located automatically on the CSE-MRI data using MRS
 252 voxel coordinates. MRI was acquired in breath-holding whereas MRS was in free breathing.
 253 This difference led to localization errors of ROI on CSE-MRI. Thus, a manual ROI
 254 repositioning was visually performed in the liver.

255 *Calculation Of FA Composition (CSE-MRI And MRS)*

256 To avoid any difference linked to data processing, the FA quantification method used the
 257 same model function and implementation for CSE-MRI (10) and MRS (19). Indeed, in this
 258 previous publication (19), it has been shown that, despite different J-evolutions between
 259 STEAM sequence and 3D CSE-MRI, the model used in CSE-MRI can be used for MRS data
 260 analysis and lead to consistent results. FA composition was determined by a fitting procedure
 261 applied in the time domain on specific points defined by the methylene chemical shift: $t =$
 262 $t=n*t_e$ with $t_e = \pi/((4.7-1.3)*B_0*\gamma) = 1.15$ ms and $n=1, \dots, 32$ for MRS processing and $n=1, \dots, 8$
 263 for CSE-MRI. The model function used was defined as:

264

$$265 \quad f(t) = \text{real} \left((Aw * n_{water} * e^{-\frac{(TE+t)}{T2w}} + Af * \sum_{k=1}^8 \left(n_k(n_{db}, n_{midb}, CL) * \right. \right.$$

$$266 \quad \left. \left. e^{2\pi i \Delta f_k t} * e^{-\frac{(TE+t)}{T2k}} \right) \right) * e^{-\frac{t}{T2'}}$$

267 where Aw and Af represent the numbers of water and triglycerides molecules respectively,
 268 $n_k(n_{db}, CL, n_{midb})$ the number of protons in the fat spectrum component k in terms of n_{db} ,
 269 CL and n_{midb} (Table 1), f_k the frequency shift between water and each fat spectrum
 270 component k, n_{water} the number of protons in a water molecule, $T2_k$ the transverse relaxation
 271 of the k^{th} peak, $T2_w$ the transverse relaxation of the water peak, and the $T2'$ the global

272 relaxation time decay induced by B0 dispersion. For MRS processing, the T2_k-values were
 273 estimated before the fitting and T2' was estimated during the processing (TE = 14 ms). For
 274 CSE-MRI processing, the global apparent T2* (1/T2* = 1/T2 + 1/T2') value was computed (TE
 275 = 0 ms). FA composition was derived from ndb and nmidb with the following relations (11):

$$PUFA_{indx} = \frac{nmidb}{3} * 100$$

$$MUFA_{indx} = \frac{(ndb - 2 * nmidb)}{3} * 100$$

$$SFA_{indx} = 100 - PUFA_{indx} - MUFA_{indx}$$

276 PUFA_{indx} is the relative proportion of polyunsaturated FA, MUFA_{indx} the relative proportion
 277 of mono-unsaturated FA and SFA_{indx} the relative proportion of saturated FA.

278 The CSE-MRI measurement of PUFA_{indx} (respectively MUFA_{indx} and SFA_{indx}) was calculated
 279 on whole-segmented volume of SAT (respectively VAT). To see the influence of the
 280 inhomogeneity of the B0 field, another calculation was also computed excluding pixels at the
 281 boundary between air/water or fat interface and pixels with an estimation of T2* under 10 ms
 282 (figure 1 in supplementary material).

283 **Statistical Analysis**

284 Anthropometric measurements are expressed as mean ± SEM. Pearson's correlation
 285 coefficient and Bland Altman plot were used to compare reference measurements (DEXA or
 286 MRS) and CSE-MRI measurements. Coefficient of variation (CV) was computed to analyze
 287 the variability of the measurements. Paired t-tests were performed to compare data from
 288 MRI1 (or MRS1) and MRI2 (or MRS2) for each quantified parameters (PDFF in the liver,
 289 volume and FA composition of AT). The normality of each data distribution was tested using
 290 the Shapiro-Wilk test. In the case of non-normal distribution, a paired sample Wilcoxon rank

291 test (non-parametric test) was performed in addition to the t-test. P-value <0.05 was
292 considered as significant. Statistical analyses were made with the software OriginPro 8.5.1
293 SR2 (OriginLab Corporation, Northampton, England).

294 **RESULTS**

295 *Subjects*

296 Baseline characteristics of 21 non-obese healthy male volunteers are summarized on Table 2.
297 An MRI examination after overfeeding could not be performed for one subject and the MRS
298 acquisitions from another subject before overfeeding were missing.

299 *Volumes*

300 *MRI vs DEXA Before Intervention*

301 On a total of 21 subjects, 18 underwent DEXA scanning on the same device (DEXA, Lunar
302 Prodigy GE Medical Systems) and three on a different one (Discovery A, Hologic, Bedford,
303 MA, USA). Only data from the first 18 subjects were used for the comparison. An excellent
304 correlation between CSE-MRI measurement of TAT and DEXA measurement of android
305 region ($r = 0.98$, $p < 0.001$) was found with a constant lower value of MRI-based estimate
306 (bias of -120g, Bland-Altman plot Figure 2). This bias represented 6% in average of the
307 android region mass. The total fat content measured by CSE-MRI considering PDFF of
308 tissues was also highly correlated to DEXA measurement of android region ($r=0.94$, $p<0.001$,
309 bias of +96g).

310 *After The Overfeeding Intervention*

311 The subjects gained 2.5 ± 0.3 kg, with a 1.6 ± 1.1 kg total fat mass gain measured by DEXA
312 (Table 2). SAT, VAT and TAT volumes quantified using CSE-MRI sequence significantly
313 increased between the two examinations ($+91 \text{ cm}^3$, $p<0.001$; $+129 \text{ cm}^3$, $p<0.001$; $+219 \text{ cm}^3$,
314 $p<0.001$ respectively). A significant increase in fat mass measured by DEXA in android

315 region was also observed (+191 g, $p=0.001$) and was correlated to the CSE-MRI
316 measurements of TAT ($r=0.80$, $p<0.001$, $n=16$). The ratio VAT/SAT also significantly
317 increased after overfeeding (+0.06, $p=0.020$).

318 *Fat Content In The Liver*

319 Hepatic fat content is low in healthy subjects and difficult to detect. In some MRS
320 measurements, fat content could not be detected: 2/20 at the baseline (MRS1). Over the total
321 of 21 subjects at baseline, one subject presented an abnormal level of PDFF in the liver
322 (PDFF>10%) based on CSE-MRI measurements (Figure 3a). Surprisingly, its corresponding
323 MRS measurement indicated a normal level of PDFF (PDFF=3.33%). This subject had a non-
324 homogeneous (figure 2 in supplementary material) fat content in the liver and the MRS
325 measurement was made in a low-fat region of the liver.

326 *Liver PDFF: MRI vs MRS*

327 At baseline, the correlation between localized CSE-MRI and MRS measurements was poor (r^2
328 = 0.50, $y=1.02x+0.57$). In Addition, the localized CSE-MRI gave larger PDFF-values (+0.60
329 percentage points). After the overfeeding, the correlation was improved ($r^2 = 0.80$,
330 $y=1.04x+0.42$) with still a larger value of CSE-MRI PDFF measurements (+0.55 percentage
331 points). Interestingly, even if the CSE-MRI seemed to give larger PDFF-values in the case of
332 low-fat content, variations of PDFF between the two examinations measured by MRS or
333 CSE-MRI were found to be very close ($r^2 = 0.77$, $y=0.92x+0.09$). Moreover, the bias between
334 these two measurements was small (larger value of localized CSE-MRI +0.05 percentage
335 points, Bland-Altman Figure 4). The Figure 4 shows an outlier point with a Δ MRS (MRS2-
336 MRS1) PDFF value at 3.37 and a Δ MRI (MRI2-MRI1) PDFF value at 0.39. We must notify
337 that the two subsequent MRS2 acquisitions of the subject gave significantly ($p<0.001$)
338 different results: 6.32% at the first acquisition and 2.46% at the second acquisition. If we

339 excluded this first acquisition and kept only the second, the MRS2-MRS1 value would be
340 consistent with other points ($r^2 = 0.85$, $y=0.98x+0.08$, bias of 0.05).

341 *Liver PDFF: After The Overfeeding Intervention*

342 MRS measurements indicated that the PDFF in liver increased significantly (+1.74, paired t-
343 test $p=0.002$) between the two examinations. Similarly, for CSE-MRI measurements, the
344 PDFF in liver increased significantly (+1.35, paired t-test $p=0.002$). As shown in the Figure
345 3a and 3c, data had a non-normal distribution (Shapiro-Wilk test $p<0.001$ for MRS1; $p<0.001$
346 for MRS2; $p<0.001$ for MRI1; $p<0.001$ for MRI2) and a non-parametric test (paired sample
347 Wilcoxon rank test) was performed (same observation: positive difference for MRS2-MRS1
348 $p<0.001$ and positive difference for MRI2-MRI1 $p<0.001$).

349 *FA Composition Of VAT And SAT*

350 Some VAT spectra were not analyzed due to poor quality of spectra (low SNR or high
351 inhomogeneity of B0 field) and were removed from the analyses: 4/20 at baseline and 3/21
352 after overfeeding. The CSE-MRI data of one subject could not be processed to estimate the
353 FA composition.

354 *FA Composition: Variabilities*

355 For CSE-MRI measurement at the first examination, the intra-subject variability was high
356 with a larger heterogeneity of n_{midb} values in VAT (mean CV of: n_{db} 28%, n_{midb} 73%, $n =$
357 20) than in SAT (mean CV of: n_{db} 23%, n_{midb} 55%). A second calculation was performed
358 excluding pixels at the boundaries of the mask and pixels with an estimation of $T2^*$ under 10
359 ms and permitted to reduce the intra-subject variability (mean CV of n_{db} 22%, n_{midb} 52% n
360 = 20 for VAT and n_{db} 16%, n_{midb} 33% $n = 20$ for SAT). The mean percentage of pixels at
361 the boundaries of the mask was 27% for SAT and 39% for VAT. 17% pixels of SAT and 24%

362 pixels of VAT had an estimated T2* under 10 ms. The mean CV of MRS measurement was
363 lower in SAT (ndb 3%, nmidb 5%, n = 20) than in VAT (ndb 11%, nmidb 21%, n = 16).

364 *FA Composition: Comparison MRS And CSE-MRI (Whole Volume)*

365 MRS and whole-volume CSE-MRI FA composition estimations were correlated (SAT: r =
366 0.82, p < 0.001 for ndb and r = 0.84, p < 0.001 for nmidb, n = 19) with a low bias (0.06 IC 95
367 % [-0.32 0.43] for ndb and 0.02 IC 95% [-0.15 0.20] for nmidb). It was however difficult to
368 compare these two methods without considering the high spatial variability (intra-subject
369 variability) of CSE-MRI measurements. As illustrated in Figure 5, the MRS value was
370 included in the range defined by the mean \pm one standard deviation of CSE-MRI
371 measurements for each subject.

372 *FA Composition: SAT And VAT*

373 Regarding CSE-MRI results from the whole segmented volume (L2 to L4) versus the
374 localized-MRS results, the comparison of FA composition of SAT and VAT appeared to be
375 substantially equivalent in average for ndb and nmidb measurements (CSE-MRI SAT vs
376 VAT: ndb = 2.43 ± 0.16 vs 2.20 ± 0.15 p < 0.001, nmidb = 0.56 ± 0.07 vs 0.46 ± 0.07 p <
377 0.001; MRS: ndb = 2.48 ± 0.29 vs 1.90 ± 0.63 p = 0.001, nmidb = 0.58 ± 0.14 vs 0.37 ± 0.22
378 p = 0.001) and for PUFA_{indx}/MUFA_{indx}/SFA_{indx} measurements (Figure 6). In both cases,
379 paired t-tests showed significant difference between SAT and VAT FA composition (p <
380 0.001 for CSE-MRI measurements and p < 0.01 for MRS measurements). The inter-subject
381 variability was higher in localized-MRS measurements than in the CSE-MRI measurements.

382 *FA Composition: Change Between The Two Examinations*

383 The same trend for the variations of all the FA composition parameters was observed based
384 on both CSE-MRI and MRS measurements for VAT (figure 7). The low inter-subject
385 variability of CSE-MRI measurement permitted to detect significant variation of adipose

386 tissue composition whereas MRS measurement did not (VAT MUFA + 1.22 percentage
387 points ($p < 0.001$) for CSE-MRI, + 0.96 percentage points ($p = 0.318$) for MRS).

388 *FA Composition: GC-MS Analysis*

389 Thirteen samples of SAT were analyzed using gas chromatography (7 before and 6 after the
390 overfeeding intervention). Results were expressed as molar percentage and are presented in
391 Table 3. Measurements by GC-MS were considered as reference.

392 Good correlations were found between GC-MS and CSE-MRI measurements (for ndb:
393 $r=0.84$, $y=0.76x+0.40$, $p=0.001$; for nmidb: $r=0.66$, $y=0.88x-0.09$, $p=0.020$). However CSE-
394 MRI measurements overestimated ndb (Bland-Altman bias=0.17 percentage points, IC 95%
395 [0.01;0.34],) and nmidb (Bland-Altman bias=0.16 percentage points, IC 95% [0.04;0.27],).
396 Better correlations were found between GC-MS and MRS measurements (for ndb: $r=0.83$,
397 $y=0.31x+1.47$, $p<0.001$; for nmidb: $r=0.74$, $y=0.36x+0.19$, $p=0.006$) however the bias was
398 larger. MRS measurements overestimated ndb (bias=0.24 percentage points, IC 95% [-
399 0.22;0.70], Bland-Altman) and nmidb (bias=0.19 percentage points, IC 95% [- 0.04;0.42],
400 Bland-Altman).

401 **DISCUSSION**

402 Consistent with the literature (24), we found that CSE-MRI-based fat mass measurements of
403 android region is strongly correlated with DEXA measurements. However, a small bias was
404 observed with slight lower value of TAT volume with CSE-MRI measurements. The DEXA
405 measurement is a 2D measurement and does not permit to distinguish VAT, SAT and other
406 ectopic fat like bone marrow and intramuscular adipose tissue. The automated segmentation
407 processing based on CSE-MRI images enabled to separate VAT from SAT. Thus, muscles
408 and bone marrow were excluded from VAT mask by a threshold empirically defined at 55%
409 using the PDFFF mapping. This exclusion could explain the difference in CSE-MRI and

410 DEXA measurements as when we considered the PDFF of muscles, vertebrae and VAT in the
411 calculation of fat content, the bias reduced. To go further in the segmentation of different
412 adipose tissue depots, some studies (25, 26) differentiated the deep (DSAT) from the
413 superficial (SSAT) subcutaneous adipose tissue in the abdominal region. This segmentation of
414 DSAT and SSAT is very challenging because the fascia superficial separating these tissues
415 appears subtle and discontinuous and need a fine resolution (~ 1.25 mm). The present in-plane
416 resolution was due to a compromise between an acquisition time compatible with breath-
417 holding and the size of the covering volume (320 mm in the head-foot direction in this study)
418 to give a good SNR which is an essential parameter to estimate the FA composition (i.e.
419 proportions of PUFA_{indx}, MUFA_{indx} and SFA_{indx}). From a metabolic point of view, GC
420 analysis of SSAT and DSAT in a large cohort shows homogenous FA composition in the two
421 adipose tissue depots (7).

422 Liver PDFF results were consistent with the literature (13–15), with a good correlation
423 established between MRS and CSE-MRI measurements. However, some studies (13–15)
424 provided a better correlation. It should be noted that the range of values was larger in these
425 papers (0 – 40 % (13–15)) than in the present paper (0 – 12 %). Especially, it is challenging to
426 accurately estimate very low fat content in liver. Here, we demonstrated that even if the PDFF
427 measurement methods with CSE-MRI or MRS were different, the difference between the two
428 PDFF measurements (before and after the overfeeding) was equivalent with the two methods.
429 In this study, no T2 correction was applied on the calculation of fat content in the liver for
430 MRS measurement. In addition, MRI method include by a priori knowledge eight fat spectral
431 component in the quantification model, that was not the case for MRS since fat quantities
432 were too low in this study. These could explain why the MRS measurement gave
433 underestimated values compared to CSE-MRI measurement. On the other hand, the CSE-MRI
434 PDFF estimate could be affected by the low SNR.

435 The lipid quantification by CSE-MRI could be interesting in longitudinal clinical studies, as
436 an indirect marker of AT metabolism. Here, the average on the whole segmented volume
437 (between L2-L4) seemed to give results consistent with the literature. Machann et al. (27)
438 reported similar results even if they computed different FA composition indexes: the
439 polyunsaturated index (PUI = diacyl-methyl ratio) and the unsaturated index (UI = olefinic-
440 methyl ratio), VAT was composed by 14.9%/48.9%/36.2% of PUFA_{indx}/MUFA_{indx}/SFA_{indx}
441 (vs 15.3%/42.7%/43.0% in our study), SAT was composed by 16.2%/56.6%/27.2% (vs
442 18.6%/43.7%/37.7% in our study). Other studies reported higher values of *nmidb* both using
443 MRS method (0.75 SCAT calf (28), 0.687/0.745 for VAT/DSAT (26), 0.71 for SCAT leg
444 (11), 0.79/0.81 for VAT/DSAT (12) than 0.37/0.58 for VAT/SAT in our study) and with MRI
445 method (0.836/0.936 for VAT/SAT (10), 0.71/0.73 for VAT/DSAT (12), 0.74 for SCAT leg
446 (11) than 0.46/0.56 for VAT/SAT in our study) which led to an estimation of PUFA superior
447 to 20%. However, several gas chromatography analysis have quantified a lower content of
448 PUFA (12.3% (29), 14.4% (30), 16.5% (9), 14.1%(31)) and lower *nmidb* (0.45(30), 0.50 (9),
449 0.63 (32)) which was more consistent with our present results. It should also be noted that the
450 PUFA_{indx} calculation made from *nmidb*, was not an absolute quantification but a coherent
451 index of polyunsaturation, leading to consistent results when the most frequently identified
452 PUFA is di-unsaturated FA. It could be possible to quantify the proportion of PUFA more
453 precisely by calculating the proportion of omega-3 (33–35) and correcting the present
454 calculation but it does not permit to know exactly the number of double bonds per chain.

455 The validation of lipid quantification by CSE-MRI using MRS measurement is a difficult
456 task. As expected, the lipid quantification by MRS is challenging and results depend on the
457 B0 field heterogeneities (26), the MRS sequences (36), the acquisition parameters (long TE or
458 short TE) (29) and the fitting approaches (37). It is therefore difficult to use it as reference. On
459 the other hand, a gold standard like gas chromatography-mass spectrometry analysis is

460 difficult to perform on human volunteers, for ethical reasons only subcutaneous adipose tissue
461 can be analyzed. In this study, good correlations were found between MRS and CSE-MRI
462 measurement, MRS and GC-MS measurements and between CSE-MRI and GC-MS
463 measurements. However, the NMR methodologies gave biased results compare to GC-MS
464 methodology. The CSE-MRI and MRS fitting approach used strong constraint on a relation
465 between ndb and $nmidb$ (10, 19) to improve the repeatability of measurements, however this
466 constraint provided biased results and not absolute quantification. Therefore, the good
467 correlation between GC-MS and NMR methodologies is already an important result, even if, a
468 comparative study using more sample should be necessary. The higher inter-subject
469 variability seen in localized-MRS measurements compared with the CSE-MRI measurements
470 could be explained first by the difficulty to locate in some lean volunteers, the MRS voxel
471 into AT only. This could induce some partial volume effects. Moreover, due to the large
472 difference between the elementary volume (8000 mm³ for MRS compared to 9.84 mm³ for
473 MRI), the local inhomogeneity is in favor of CSE-MRI despite a dedicated localized shim for
474 MRS. Finally, the value estimated by CSE-MRI resulted from an averaging over a large
475 number of pixels (>10000 pixels) which attenuated the effect of potential aberrant individual
476 values for each subjects, unlike for the MRS where only two measurements were made. The
477 spatial non-uniformity of $nmidb$ was larger in VAT than in SAT. This high spatial variability
478 could be due to a sensitivity of CSE-MRI FA composition measurements to local field
479 inhomogeneity as the coefficient of variation reduced when we removed pixels located at fat-
480 air interface. This local field inhomogeneity is due to high contribution of internal field as
481 regard to fat-tissue interface where susceptibility gradient is strong. To increase spatial
482 resolution may probably minimize this effect. Alternatively, to provide more consistent
483 measurements, it is possible to suppress these voxels in the segmentation pipeline such as
484 proposed in this study. Moreover, VAT tissue could be more impacted by local field

485 inhomogeneity due to the presence of air in the gut. In localized area, this sensitivity to local
486 field heterogeneities led to erroneous values of CSE-MRI measurements. For the study of
487 localized area, localized-MRS seemed to still be the best method thanks to shim methods
488 allowing to homogenize locally the magnetic field. Visual analysis of spectrum permits to
489 validate results with consistent fitting approach. Moreover, in the literature, only methods of
490 spectroscopy make the quantification of omega-3 possible (33–35). A limitation of our study
491 concerned the design of the overfeeding. This was a short term 31-days overfeeding, and as
492 the half-life of subcutaneous adipose tissue fatty acids is around 6 to 9 months (9), the
493 overfeeding may have been too short to detect a change in SAT fatty composition with the
494 diet.

495 To conclude, significant increase in fat distribution in VAT, SAT and liver were measured by
496 DEXA, MRS and CSE-MRI measurements after an experimental overfeeding. FA
497 composition changes (more precisely the MUFA proportion) of the adipose tissue were also
498 observed by CSE-MRI measurements. The use of a single 3D CSE-MRI sequence associated
499 with a dedicated post processing method is a suitable protocol to follow several parameters
500 linked to adipose tissue changes. This NMR protocol could be used in future work to evaluate
501 non-invasively the impact of nutrition on adipose tissues and liver.

502

503 **Acknowledgments:**

504 This study was conducted as part of the LABEX PRIMES (ANR-11-LABX-0063) of the
505 “Université de Lyon”, within the "Investissements d'Avenir" program (ANR-11-IDEX-0007)
506 operated by the French National Research Agency (ANR). This study was also supported by
507 the IHU OpéRa (ANR-10-IBHU-0004), within the "Investissements d'Avenir" program
508 operated by the French National Research Agency (ANR). We thank Corinne Louche-
509 Pelissier and Adeline Cestre (CRNH-RA) for technical assistance in the fatty acid analyse
510 using GC-MS.

511 **References**

- 512 1. Heymsfield SB, Wadden TA: Mechanisms, Pathophysiology, and
513 Management of Obesity. *N Engl J Med* 2017; 376:254–266.
- 514 2. Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT: Visceral and
515 Intrahepatic Fat Are Associated with Cardiometabolic Risk Factors Above Other
516 Ectopic Fat Depots: The Framingham Heart Study. *Am J Med* 2018; 131:684-
517 692.e12.
- 518 3. Alligier M, Gabert L, Meugnier E, et al.: Visceral Fat Accumulation During
519 Lipid Overfeeding Is Related to Subcutaneous Adipose Tissue Characteristics in
520 Healthy Men. *J Clin Endocrinol Metab* 2013; 98:802–810.
- 521 4. Chowdhury B, Sjöström L, Alpsten M, Kostanty J, Kvist H, Löfgren R: A
522 multicompartiment body composition technique based on computerized
523 tomography. *Int J Obes Relat Metab Disord J Int Assoc Study Obes* 1994;
524 18:219–234.
- 525 5. Hu HH, Kan HE: Quantitative proton MR techniques for measuring fat. *NMR*
526 *Biomed* 2013; 26:1609–1629.
- 527 6. Reeder SB, Hu HH, Sirlin CB: Proton density fat-fraction: A standardized mr-
528 based biomarker of tissue fat concentration. *J Magn Reson Imaging* 2012;
529 36:1011–1014.
- 530 7. Petrus P, Edholm D, Rosqvist F, et al.: Depot-specific differences in fatty acid
531 composition and distinct associations with lipogenic gene expression in
532 abdominal adipose tissue of obese women. *Int J Obes* 2017; 41:1295–1298.
- 533 8. Jové M, Moreno-Navarrete JM, Pamplona R, Ricart W, Portero-Otín M,
534 Fernández-Real JM: Human omental and subcutaneous adipose tissue exhibit
535 specific lipidomic signatures. *FASEB J* 2013; 28:1071–1081.
- 536 9. Hodson L, Skeaff CM, Fielding BA: Fatty acid composition of adipose tissue
537 and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res*
538 2008; 47:348–380.
- 539 10. Leporq B, Lambert SA, Ronot M, Vilgrain V, Van Beers BE: Quantification
540 of the triglyceride fatty acid composition with 3.0 T MRI. *NMR Biomed* 2014;
541 27:1211–1221.
- 542 11. Peterson P, Månsson S: Simultaneous quantification of fat content and fatty
543 acid composition using MR imaging. *Magn Reson Med* 2013; 69:688–697.

- 544 12. Bydder M, Girard O, Hamilton G: Mapping the double bonds in
545 triglycerides. *Magn Reson Imaging* 2011; 29:1041–1046.
- 546 13. Achmad E, Yokoo T, Hamilton G, et al.: Feasibility of and agreement
547 between MR imaging and spectroscopic estimation of hepatic proton density fat
548 fraction in children with known or suspected nonalcoholic fatty liver disease.
549 *Abdom Imaging* 2015; 40:3084–3090.
- 550 14. Zand KA, Shah A, Heba E, et al.: Accuracy of multiecho magnitude-based
551 MRI (M-MRI) for estimation of hepatic proton density fat fraction (PDFFF) in
552 children. *J Magn Reson Imaging* 2015; 42:1223–1232.
- 553 15. Tyagi A, Yeganeh O, Levin Y, et al.: Intra- and inter-examination
554 repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and
555 complex-based MRI for estimation of hepatic proton density fat fraction in
556 overweight and obese children and adults. *Abdom Imaging* 2015; 40:3070–3077.
- 557 16. Stults-Kolehmainen MA, Stanforth PR, Bartholomew JB, Lu T, Abolt CJ,
558 Sinha R: DXA estimates of fat in abdominal, trunk and hip regions varies by
559 ethnicity in men. *Nutr Diabetes* 2013; 3:e64.
- 560 17. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and
561 purification of total lipides from animal tissues. *J Biol Chem* 1957; 226:497–
562 509.
- 563 18. Gabert L, Vors C, Louche-Pélissier C, et al.: ¹³C tracer recovery in human
564 stools after digestion of a fat-rich meal labelled with [1,1,1-¹³C]tripalmitin and
565 [1,1,1-¹³C]triolein. *Rapid Commun Mass Spectrom* ; 25:2697–2703.
- 566 19. Nemeth A, Segrestin B, Leporq B, et al.: Comparison of MRI-derived vs.
567 traditional estimations of fatty acid composition from MR spectroscopy signals.
568 *NMR Biomed* 2018; 31:e3991.
- 569 20. Ratiney H, Bucur A, Sdika M, Beuf O, Pilleul F, Cavassila S: Effective voigt
570 model estimation using multiple random starting values and parameter bounds
571 settings for in vivo hepatic ¹H magnetic resonance spectroscopic data. In 2008
572 *5th IEEE Int Symp Biomed Imaging Nano Macro*; 2008:1529–1532.
- 573 21. Leporq B, Ratiney H, Pilleul F, Beuf O: Liver fat volume fraction
574 quantification with fat and water T1 and T2* estimation and accounting for
575 NMR multiple components in patients with chronic liver disease at 1.5 and 3.0
576 T. *Eur Radiol* 2013; 23:2175–2186.
- 577 22. Lankton S, Tannenbaum A: Localizing Region-Based Active Contours.
578 *IEEE Trans Image Process* 2008; 17:2029–2039.

- 579 23. Snyder W, Cook M, Nasset E, Karhausen L, Parry Howells G, Tipton I:
580 Report of the Task Group on Reference Man. International Commission on
581 radiological protection, no. 23. Pergamon Press: Oxford; 1975.
- 582 24. Silver HJ, Niswender KD, Kullberg J, et al.: Comparison of Gross Body Fat-
583 Water Magnetic Resonance Imaging at 3 Tesla to Dual Energy X-Ray
584 Absorptiometry in Obese Women. *Obes Silver Spring Md* 2013; 21:765.
- 585 25. Sadananthan SA, Prakash B, Leow MK-S, et al.: Automated segmentation of
586 visceral and subcutaneous (deep and superficial) adipose tissues in normal and
587 overweight men. *J Magn Reson Imaging* 2015; 41:924–934.
- 588 26. Hamilton G, Schlein AN, Middleton MS, et al.: In vivo triglyceride
589 composition of abdominal adipose tissue measured by 1H MRS at 3T. *J Magn*
590 *Reson Imaging* 2017; 45:1455–1463.
- 591 27. Machann J, Stefan N, Wagner R, et al.: Intra- and interindividual variability
592 of fatty acid unsaturation in six different human adipose tissue compartments
593 assessed by 1H-MRS in vivo at 3 T. *NMR Biomed* 2017; 30:e3744.
- 594 28. Ren J, Dimitrov I, Sherry AD, Malloy CR: Composition of adipose tissue
595 and marrow fat in humans by 1H NMR at 7 Tesla. *J Lipid Res* 2008; 49:2055–
596 2062.
- 597 29. Lundbom J, Hakkarainen A, Fielding B, et al.: Characterizing human
598 adipose tissue lipids by long echo time 1H-MRS in vivo at 1.5 Tesla: validation
599 by gas chromatography. *NMR Biomed* 2010; 23:466–472.
- 600 30. Field CJ, Angel A, Clandinin MT: Relationship of diet to the fatty acid
601 composition of human adipose tissue structural and stored lipids. *Am J Clin Nutr*
602 1985; 42:1206–1220.
- 603 31. Rosqvist F, Iggman D, Kullberg J, et al.: Overfeeding Polyunsaturated and
604 Saturated Fat Causes Distinct Effects on Liver and Visceral Fat Accumulation in
605 Humans. *Diabetes* 2014; 63:2356–2368.
- 606 32. Garaulet M, Hernandez-Morante JJ, Lujan J, Tebar FJ, Zamora S:
607 Relationship between fat cell size and number and fatty acid composition in
608 adipose tissue from different fat depots in overweight/obese humans. *Int J Obes*
609 2006; 30:899–905.
- 610 33. Lundbom J, Heikkinen S, Fielding B, Hakkarainen A, Taskinen M-R,
611 Lundbom N: PRESS echo time behavior of triglyceride resonances at 1.5T:
612 Detecting ω -3 fatty acids in adipose tissue in vivo. *J Magn Reson* 2009; 201:39–
613 47.

- 614 34. Fallone CJ, McKay RT, Yahya A: Long TE STEAM and PRESS for
615 estimating fat olefinic/methyl ratios and relative ω -3 fat content at 3T. *J Magn*
616 *Reson Imaging* 2018; 48:169–177.
- 617 35. Škoch A, Tošner Z, Hájek M: The in vivo J-difference editing MEGA-
618 PRESS technique for the detection of n-3 fatty acids. *NMR Biomed* 2014;
619 27:1293–1299.
- 620 36. Hamilton G, Middleton MS, Bydder M, et al.: Effect of PRESS and STEAM
621 sequences on magnetic resonance spectroscopic liver fat quantification. *J Magn*
622 *Reson Imaging* 2009; 30:145–152.
- 623 37. Mosconi E, Sima DM, Osorio Garcia MI, et al.: Different quantification
624 algorithms may lead to different results: a comparison using proton MRS lipid
625 signals. *NMR Biomed* 2014; 27:431–443.
- 626
- 627

628 **Tables**

Table 1. Parameters conditioning the fat spectrum model used				
Component k	Type	Δf_k (Hz)	Chemical shift (ppm)	$n_k(\text{ndb}, \text{nmidb}, \text{CL})$
1	Olefinic + Glycerol	-74.9	5.29 5.19	2 x ndb +1
water	-	0	4.70	$n_{\text{water}} = 2$
2	Glycerol	63.5	4.20	4
3	Dyacyl	247.7	2.75	2 x nmidb
4	α -carboxyl	312.4	2.24	6
5	α -olefinic	340.4	2.02	4 x (ndb-nmidb)
6	β -carboxyl	393.7	1.60	6
7	Methylene	431.8	1.30	$6x(\text{CL}-4)-8 \text{ x ndb} + 2 \text{ x nmidb}$
8	Methyl	482.6	0.90	9

629 **Table 1:** Parameters conditioning the fat spectrum model used. Δf_k , frequency shift between water and each fat
630 resonance.

631

	Baseline	After the overfeeding intervention	Differences
Age	33±2		
Body weight(kg)	79.6±1.6	82.4±1.6	2.6±0.3*** (n = 21)
Body Mass index (kg/m ²)	25.2±0.3	26.0±0.3	0.8±0.1*** (n = 21)
DEXA			
fat mass of whole body (kg)	19.6±1.2	21.2±1.1	1.6±1.1*** (n = 21)
fat mass of android region (kg)	1.85±0.13	2.07±0.57	0.19±0.04** (n = 20, p=0.001)
CSE-MRI			
SAT volume(cm ³)	1104±74	1191±79	91±22*** (n=20)
VAT volume (cm ³)	922±104	1070±116	129±31*** (n=20)
TAT volume (cm ³)	2027±745	2261±765	219±41*** (n=20)
VAT/SAT	0,83±0,08	0,91±0,09	0,06±0,03* (n=20, p=0.020)
liver PDFF	2.70±0.54	4.05±0.87	1.35±0.39** (n=20, p=0.003)
localized liver PDFF	1.73± 0.34	3.38 ± 0.77	1.66 ± 0.53** (n=19, p=0.006)

FA composition of SAT	ndb = 2.43 ± 0.04	2.43 ± 0.03	0.00 ± 0.01 (n=19, p=0.812)
	nmidb = 0.56 ± 0.02	0.55 ± 0.01	0.00 ± 0.01 (n=19, p=0.612)
FA composition of VAT	ndb = 2.20 ± 0.03	2.19 ± 0.03	-0.01 ± 0.02 (n=19, p=0.512)
	nmidb = 0.46 ± 0.02	0.44 ± 0.01	$-0.03 \pm 0.01^*$ (n=19, p=0.013)
MRS			
liver PDFF	1.20 ± 0.23	3.02 ± 0.31	$1.74 \pm 0.48^{**}$ (n=20, p=0.002)
FA composition of SAT	ndb = 2.48 ± 0.06	2.45 ± 0.07	-0.05 ± 0.05 (n=20, p=0.381)
	nmidb = 0.58 ± 0.03	0.57 ± 0.03	-0.02 ± 0.03 (n=20, p=0.417)
FA composition of VAT	ndb = 1.90 ± 0.16	2.04 ± 0.11	0.19 ± 0.17 (n=15, p=0.290)
	nmidb = 0.37 ± 0.06	0.41 ± 0.04	0.06 ± 0.06 (n=15, p=0.395)

632

633 **Table 2: Measurements of the cohort before and after overfeeding. Data are expressed as mean SEM. * indicate significant difference due to overfeeding paired t-test ***p<0.001.**634 **SAT: abdominal subcutaneous adipose tissue from L2 to L4; VAT: visceral adipose tissue from L2 to L4; TAT: total abdominal adipose tissue (SAT+VAT); PDFF: proton density fat**635 **fraction; FA: fatty acid; ndb, number of double bonds; nmidb, number of methylene-interrupted double bonds.**

636

	Fatty acid	Mean	SD
SFA (%)	C12	0.80	0.17
	C14	4.99	0.48
	C15	0.47	0.03
	C16	27.40	1.31
	C18	4.32	0.63
	C20	0.12	0.02
MUFA (%)	C14:1	0.49	0.12
	C16:1	4.46	1.14
	C18:1n9t	0.47	0.08
	C18:1n9c	42.15	1.3
	C18:1n7	1.75	0.09
	C20:1	0.45	0.03
PUFA (%)	C18:2n6c	11.09	2.32
	C20:2	0.15	0.01
	C18:3n3	0.68	0.18
	C20:4n6	0.20	0.05
PUFA (%)		12.12	2.44
MUFA (%)		49.78	2.27
SFA (%)		38.10	1.98
ndb_{GC}		2.25	0.12
nmidb_{GC}		0.40	0.08
CL_{GC}		17.10	0.06
PUFA_{indx} (%)		13.21	2.57
MUFA_{indx} (%)		48.69	2.37
SFA_{indx} (%)		38.10	1.98

637 Table 2: Molar percentage of the different fatty acid of human subcutaneous adipose tissue determined by gas
638 chromatography (n = 13). PUFA_{indx}, MUFA_{indx} and SFA_{indx} were computed using ndb_{GC} and nmidb_{GC}.

639

640

641 **Figure Legends**

642 Figure 1: A STEAM sequence was acquired in liver, subcutaneous adipose tissue
643 (SAT) and visceral adipose tissue (VAT) using the following parameters: TR = 3000 ms,
644 TE= 14 ms, TM= 10 ms, VOI of 20×20×20 mm³, no water suppression, 2048 Hz bandwidth,
645 1024 data points, 4 signal averages for VAT and SAT and 32 signal averages for the liver. For
646 SAT and VAT, further acquisitions were made with TE = [24, 34, 44, 54, 64] ms.

647 Figure 2: The total abdominal adipose tissue (TAT) volume delimited by the lumbar
648 vertebrae L2 and L4 was calculated using CSE-MRI. This volume was converted into mass
649 using the assumed density of 0.92 g/cm³ and compared to the DEXA measurement on
650 android region. The dotted line in the left part of this graph represents the identity line.

651 Figure 3: Dots represent the value of the proton density fat fraction (PDFF) in the liver
652 for each subject and are represented in a boxplot beside dots. Figures a) and b) show CSE-
653 MRI measurements. Figures c) and d) show MRS measurements. In figures a) and c) data
654 before overfeeding (MRI1 and MRS1) are in pink color and data after the overfeeding (MRI2
655 and MRS2) in blue. In figures b) and d) the difference between the two examinations was
656 illustrated. Paired t-test was performed between MRI1 and MRI2 for the PDFF in the liver.
657 Significant difference between the two examinations was shown by Paired t-test (** p-value <
658 0.01) and Wilcoxon rank test (p<0.001), n = 20, . The PDFF increased significantly (+ 1.35, p
659 = 0.002 for CSE-MRI measurements; + 1.74, p = 0.002 for MRS measurements).


660 Figure 4: The left part of this graph shows a good correlation between Δ MRI
661 (localized MRI2-MRI1 measurement) and Δ MRS (MRS2-MRS1 measurement). The
662 Pearson's coefficient was $r = 0.88$, $p < 0.001$. The Bland-Altman in the right part of the graph
663 shows a little bias of 0.05.

664 Figure 5: For each subject (n = 21, baseline examination, abdominal subcutaneous
665 adipose tissue), the mean value of ndb (a) and nmldb (b) is in red color for CSE-MRI
666 measurement and in black for MRS measurement. The error bars represent the standard
667 deviation in the whole volume studied for CSE-MRI measurements and the mean deviation
668 between the MRS test-retest measurements. The CSE-MRI measurements of subject '1' were
669 missing. The MRS measurements of subject '20' were missing.

670 Figure 6: Bars represent the mean value of PUFAindx (resp. MUFAindx and
671 SFAindx) and error bars represent the standard deviation (inter-subject variability) for the
672 tissue VAT (visceral adipose tissue) and SAT (abdominal subcutaneous adipose tissue)
673 measured a) by MRS and b) by CSE-MRI method. Paired t-tests were performed between
674 values from SAT against values from VAT for PUFAindx, MUFAindx and SFAindx
675 measurements. *** $p < 0.001$, ** $p < 0.01$.


676 Figure 7: Dots represent the difference between the baseline measurement and after
677 the overfeeding. The inter-subject of MRS measurement was higher than CSE-MRI
678 measurement. Paired t-tests were performed between the two examinations (SAT:
679 PUFAindx/MUFAindx/SFAindx - 0.12 ($p = 0.356$)/0.34 ($p = 0.001$)/-0.23 ($p = 0.356$) n = 19
680 for CSE-MRI and -0.94 ($p = 0.416$)/-0.20 ($p = 0.314$)/ 1.15 ($p = 0.354$) n = 18 for MRS; VAT:
681 -0.84 ($p = 0.012$)/1.22 ($p < 0.001$)/-0.38 ($p = 0.349$) n = 19 for CSE-MRI and -0.38 ($p =$
682 0.604)/0.96 ($p = 0.318$)/ -0.58 ($p = 0.443$) n = 13 for MRS).

683




684

685 **Figure 1**



686


687 **Figure 2**



688


689 **Figure 3**

Δ PDFFF (in %) in liver




690

691 **Figure 4**




692

693 **Figure 5**




694

695 **Figure 6**




696

697 **Figure 7**



Supplementary figure 1: Procedure of pixel exclusion after the initial segmentation to compute the mean *ndb* (number of double bonds) and *nmidb* (number of methylene-interrupted double bonds). Pictures in grey scale are displaying the subcutaneous and visceral adipose tissue masks merged with the PDFF maps. Pictures in color scale are displaying the subcutaneous and visceral adipose tissue masks merged with the *ndb* and *nmidb* maps.



Supplementary figure 2: Two examples of exams with different PDFF distribution in the liver. 3D MRI acquisition parameters were the following : 8 echoes (n x 1.15 ms TE with n=1, ...,8), 5° flip angle, 10.3 ms TR, 384 x 420 x 320 mm³ FOV, 256 x 256 x 80 matrix size, 20.8 s scan time. This acquisition was made in breath-holding. The first (out of phase) and second (in-phase) echoes as well as the PDFF map are displayed.